Radiopharmaceutical for Diagnosing Recurrence and Metastasis
Pursuing Insurance Coverage and Expanded Indications

FutureChem has obtained approval for a new radiopharmaceutical for the diagnosis of prostate cancer.


FutureChem company logo image. FutureChem

FutureChem company logo image. FutureChem

View original image

According to industry sources on May 4, FutureChem announced via a disclosure that its Positron Emission Tomography (PET) diagnostic agent, Prostview Injection (compound name: Florastamin), has received product approval from the Ministry of Food and Drug Safety. The approval date is April 30, 2026. The application for this product was submitted on July 10, 2025.


Prostview Injection is a diagnostic drug used to more accurately identify lesions in patients with recurrent or metastatic prostate cancer who have shown abnormal findings in previous imaging tests.


This product can be used not only for definitive diagnosis to confirm the presence of lesions, but also for initial staging and restaging in recurrent patients. In particular, it is expected to help establish treatment strategies by enabling early detection of micrometastases and to reduce unnecessary treatments caused by false positives.



The company plans to consider whether the product will be covered by national health insurance and to conduct post-marketing surveillance and additional clinical studies to evaluate diagnostic accuracy and safety in real clinical settings. Through these efforts, FutureChem aims to explore the potential for expanding indications.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing